Biosimilars: development and investigation using achievements in modern biotechnology
Biosimilars are biological drug products that have an equivalent clinical profile with innovator biotherapeutics but are developed under a reduced program. To this end, specific comparability approaches are followed based on reverse engineering that involves a thorough analysis of the innovator biot...
Saved in:
| Main Authors: | R. R. Niyazov, M. A. Dranitsyna, A. N. Vasiliev, E. V. Gavrishina |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2021-02-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12576 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01) -
Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01) -
Selecting the best-value biosimilar in emerging countries
by: Gilberto Castañeda-Hernández
Published: (2024-09-01) -
A Double-blind Randomized Comparative Phase I Study to Assess Biosimilarity and Immunogenicity of "Trastuzumab" (LLC "Mabscale", Russia) and Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Volunteers
by: M. A. Kolganova, et al.
Published: (2023-09-01) -
Biosimilars - drugs of the future
by: E. A. Eltcova, et al.
Published: (2014-04-01)